Фармакотерапия фиброза печени в исходе неалкогольного стеатогепатита
https://doi.org/10.22416/1382-4376-2021-31-5-16-24
Аннотация
Цель обзора: описать современное состояние проблемы фармакотерапии ассоциированного с неалкогольным стеатогепатитом (НАСГ) фиброза печени.
Основные положения. В соответствии с текущими клиническими рекомендациями лечебные мероприятия при неалкогольной жировой болезни печени должны заключаться в изменении образа жизни, нормализации массы тела, специфической фармакотерапии ассоциированного с НАСГ фиброза печени и лечении связанных с метаболическим синдромом заболеваний. Несмотря на отсутствие утвержденных схем антифибротической терапии при НАСГ, существует ряд препаратов, которые в клинических испытаниях фазы 3 продемонстрировали адекватный профиль эффективности и безопасности у разных больных, включая пациентов с компенсированным циррозом печени. Это позволяет одобрить их для проверки и подтверждения практической пользы в клинических испытаниях фазы 4.
Заключение. Учитывая, что развитие фиброза печени является неблагоприятным событием естественного течения неалкогольной жировой болезни печени, очевидно, что скорейшее внедрение и широкое применение методов антифибротической терапии улучшит результаты лечения НАСГ и позволит избежать связанных с ним осложнений.
Об авторе
Д. В. Гарбузенко
ГБОУ ВПО «Южно-Уральский государственный медицинский университет» Министерства здравоохранения Российской Федерации
Россия
Россия
Гарбузенко Дмитрий Викторович — доктор медицинских наук, профессор кафедры факультетской хирургии
454092, г. Челябинск, ул. Воровского, д. 64
Список литературы
1. Ивашкин В.Т., Маевская М.В., Павлов Ч.С., Тихонов И.Н., Широкова Е.Н., Буеверов А.О. и др. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. Рос журн гастроэнтерол гепатол колопроктол. 2016;26(2):24–42. DOI: 10.22416/1382-4376-2016-26-2-24-42
2. Adams L.A., Roberts S.K., Strasser S.I., Mahady S.E., Powell E., Estes C., et al. Nonalcoholic fatty liver disease burden: Australia, 2019–2030. J Gastroenterol Hepatol. 2020;35(9):1628–35. DOI: 10.1111/jgh.15009
3. Byrne C.D., Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62(Suppl 1):S47–64. DOI: 10.1016/j.jhep.2014.12.012
4. Chalasani N., Younossi Z., Lavine J.E., Charlton M., Cusi K., Rinella M., et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57. DOI: 10.1002/hep.29367
5. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO. Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–402. DOI: 10.1016/j.jhep.2015.11.004
6. Wong V.W., Chan W.K., Chitturi S., Chawla Y., Dan Y.Y., Duseja A., et al. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33(1):70–85. DOI: 10.1111/jgh.13857
7. Italian Association for the Study of the Liver (AISF). AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. Dig Liver Dis. 2017;49(5):471–83. DOI: 10.1016/j.dld.2017.01.147
8. Leoni S., Tovoli F., Napoli L., Serio I., Ferri S., Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol. 2018;24(30):3361–73. DOI: 10.3748/wjg.v24.i30.3361
9. Roskilly A., Hicks A., Taylor E.J., Jones R., Parker R., Rowe I.A. Fibrosis progression rate in a systematic review of placebo-treated nonalcoholic steatohepatitis. Liver Int. 2021;41(5):982–95. DOI: 10.1111/liv.14749
10. Mikolasevic I., Filipec-Kanizaj T., Mijic M., Jakopcic I., Milic S., Hrstic I., et al. Nonalcoholic fatty liver disease and liver transplantation — Where do we stand? World J Gastroenterol. 2018;24(14):1491–506. DOI: 10.3748/wjg.v24.i14.1491
11. Younossi Z.M., Stepanova M., Ong J., Trimble G., AlQahtani S., Younossi I., et al. Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States. Clin Gastroenterol Hepatol. 2021;19(3):580–9. DOI: 10.1016/j.cgh.2018.05.057
12. Anania F.A., Dimick-Santos L., Mehta R., Toerner J., Beitz J. Nonalcoholic Steatohepatitis: Current Thinking From the Division of Hepatology and Nutrition at the Food and Drug Administration. Hepatology. 2021;73(5):2023– 7. DOI: 10.1002/hep.31687
13. Longerich T., Schirmacher P. Determining the reliability of liver biopsies in NASH clinical studies. Nat Rev Gastroenterol Hepatol. 2020;17(11):653–4. DOI: 10.1038/s41575-020-00363-8
14. Cheah M.C., McCullough A.J., Goh G.B. Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease. J Clin Transl Hepatol. 2017;5(3):261–71. DOI: 10.14218/JCTH.2017.00009
15. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., et al.; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21. DOI: 10.1002/hep.20701
16. Angulo P., Kleiner D.E., Dam-Larsen S., Adams L.A., Bjornsson E.S., Charatcharoenwitthaya P., et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015;149(2):389– 97. DOI: 10.1053/j.gastro.2015.04.043
17. Brunt E.M., Kleiner D.E., Wilson L.A., Sanyal A.J., Neuschwander-Tetri B.A.; Nonalcoholic Steatohepatitis Clinical Research Network. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials. Hepatology. 2019;70(2):522–31. DOI: 10.1002/hep.30418
18. Kleiner D.E., Brunt E.M., Wilson L.A., Behling C., Guy C., Contos M., et al.; Nonalcoholic Steatohepatitis Clinical Research Network. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. JAMA Netw Open. 2019;2(10):e1912565. DOI: 10.1001/jamanetworkopen.2019.12565
19. Campos-Murguía A., Ruiz-Margáin A., González-Regueiro J.A., Macías-Rodríguez R.U. Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol. 2020;26(39):5919–43. DOI: 10.3748/wjg.v26.i39.5919
20. Galli F., Azzi A., Birringer M., Cook-Mills J.M., Eggersdorfer M., Frank J., et al. Vitamin E: Emerging aspects and new directions. Free Radic Biol Med. 2017;102:16–36. DOI: 10.1016/j.freeradbiomed.2016.09.017
21. Xu R., Tao A., Zhang S., Deng Y., Chen G. Association between vitamin E and non-alcoholic steatohepatitis: a meta-analysis. Int J Clin Exp Med. 2015;8(3):3924–34. PMID: 26064294
22. Sanyal A.J., Chalasani N., Kowdley K.V., McCullough A., Diehl A.M., Bass N.M., et al.; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362(18):1675–85.
23. Vilar-Gomez E., Vuppalanchi R., Gawrieh S., Ghabril M., Saxena R., Cummings O.W., et al. Vitamin E Improves Transplant-Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis. Hepatology. 2020;71(2):495–509. DOI: 10.1056/NEJMoa0907929
24. Lutchman G., Promrat K., Kleiner D.E., Heller T., Ghany M.G., Yanovski J.A., et al. Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin Gastroenterol Hepatol. 2006;4(8):1048–52. DOI: 10.1016/j.cgh.2006.05.005
25. Cusi K., Orsak B., Bril F., Lomonaco R., Hecht J., OrtizLopez C., et al. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial. Ann Intern Med. 2016;165(5):305–15. DOI: 10.7326/M15-1774
26. Bril F., Kalavalapalli S., Clark V.C., Lomonaco R., Soldevila-Pico C., Liu I.C., et al. Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes. Clin Gastroenterol Hepatol. 2018;16(4):558–66. DOI: 10.1016/j.cgh.2017.12.001
27. Musso G., Cassader M., Paschetta E., Gambino R. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis. JAMA Intern Med. 2017;177(5):633–40. DOI: 10.1001/jamainternmed.2016.9607
28. Lefebvre E., Moyle G., Reshef R., Richman L.P., Thompson M., Hong F., et al. Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis. PLoS One. 2016;11(6):e0158156. DOI: 10.1371/journal.pone.0158156
29. Friedman S.L., Ratziu V., Harrison S.A., Abdelmalek M.F., Aithal G.P., Caballeria J., et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatology. 2018;67(5):1754–67. DOI: 10.1002/hep.29477
30. Ratziu V., Sanyal A., Harrison S.A., Wong V.W., Francque S., Goodman Z., et al. Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. Hepatology. 2020;72(3):892–905. DOI: 10.1002/hep.31108
31. Markham A., Keam S.J. Obeticholic Acid: First Global Approval. Drugs. 2016;76(12):1221–6. DOI: 10.1007/s40265-016-0616-x
32. Mudaliar S., Henry R.R., Sanyal A.J., Morrow L., Marschall H.U., Kipnes M., et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology. 2013;145(3):574–82. DOI: 10.1053/j.gastro.2013.05.042
33. Neuschwander-Tetri B.A., Loomba R., Sanyal A.J., Lavine J.E., Van Natta M.L., Abdelmalek M.F., et al.; NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385(9972):956–65. DOI: 10.1016/S0140-6736(14)61933-4
34. Chalasani N., Abdelmalek M.F., Loomba R., Kowdley K.V., McCullough A.J., Dasarathy S., et al. Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis. Liver Int. 2019;39(5):924–32. DOI: 10.1111/liv.13974
35. Younossi Z.M., Ratziu V., Loomba R., Rinella M., Anstee Q.M., Goodman Z., et al.; REGENERATE Study Investigators. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394(10215):2184–96. DOI: 10.1016/S0140-6736(19)33041-7
36. Loomba R., Sanyal A.J., Kowdley K.V., Terrault N., Chalasani N.P., Abdelmalek M.F., et al. Factors Associated with Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis. Gastroenterology. 2019;156(1):88–95. DOI: 10.1053/j.gastro.2018.09.021
37. Li T., Chiang J.Y.L. Bile acid-based therapies for nonalcoholic steatohepatitis and alcoholic liver disease. Hepatobiliary Surg Nutr. 2020;9(2):152–69. DOI: 10.21037/hbsn.2019.09.03
38. Harrison S.A., Rossi S.J., Paredes A.H., Trotter J.F., Bashir M.R., Guy C.D., et al. NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis. Hepatology. 2020;71(4):1198– 212. DOI: 10.1002/hep.30590
39. Harrison S.A., Neff G., Guy C.D., Bashir M.R., Paredes A.H., Frias J.P., et al. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients with Nonalcoholic Steatohepatitis. Gastroenterology. 2021;160(1):219–31. DOI: 10.1053/j.gastro.2020.08.004
40. Ratziu V., Harrison S.A., Francque S., Bedossa P., Lehert P., Serfaty L., et al.; GOLDEN-505 Investigator Study Group. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology. 2016;150(5):1147–59. DOI: 10.3390/ijerph16224334
41. Shimizu M., Suzuki K., Kato K., Jojima T., Iijima T., Murohisa T., et al. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab. 2019;21(2):285–92. DOI: 10.1111/dom.13520
42. Loomba R., Lawitz E., Mantry P.S., Jayakumar S., Caldwell S.H., Arnold H., et al.; GS-US-384-1497 Investigators. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology. 2018;67(2):549–59. DOI: 10.1002/hep.29514
43. Harrison S.A., Wong V.W., Okanoue T., Bzowej N., Vuppalanchi R., Younes Z., et al.; STELLAR-3 and STELLAR-4 Investigators. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. J Hepatol. 2020;73(1):26–39. DOI: 10.1016/j.jhep.2020.02.027
44. Loomba R., Kayali Z., Noureddin M., Ruane P., Lawitz E.J., Bennett M., et al. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients with Nonalcoholic Fatty Liver Disease. Gastroenterology. 2018;155(5):1463–73. DOI: 10.1053/j.gastro.2018.07.027
45. Loomba R., Noureddin M., Kowdley K.V., Kohli A., Sheikh A., Neff G., et al.; ATLAS Investigators. Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASH. Hepatology. 2021;73(2):625–43. DOI: 10.1002/hep.31622
46. Armstrong M.J., Gaunt P., Aithal G.P., Barton D., Hull D., Parker R., et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679–90. DOI: 10.1016/S0140-6736(15)00803-X
47. Newsome P.N., Buchholtz K., Cusi K., Linder M., Okanoue T., Ratziu V., et al.; NN9931-4296 Investigators. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021;384(12):1113–24. DOI: 10.1056/NEJMoa2028395
48. Sharpton S.R., Maraj B., Harding-Theobald E., Vittinghoff E., Terrault N.A. Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. Am J Clin Nutr. 2019;110(1):139–49. DOI: 10.1093/ajcn/nqz042
49. Ratziu V., Guevara L., Safadi R., Poordad F., Fuster F., Flores-Figueroa J., et al. One-year results of the global phase 2b randomized placebo-controlled arrest trial of aramchol, a steroyl CoA desaturase inhibitor, in patients with NASH. AASLD Liver Meeting, abstract LB-5, 2018.
50. Federico A., Dallio M., Loguercio C. Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years. Molecules. 2017;22(2):191. DOI: 10.3390/molecules22020191
51. Wah Kheong C., Nik Mustapha N.R., Mahadeva S. A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2017;15(12):1940–9. DOI: 10.1016/j.cgh.2017.04.016
Рецензия
Для цитирования:
Гарбузенко Д.В. Фармакотерапия фиброза печени в исходе неалкогольного стеатогепатита. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(5):16-24. https://doi.org/10.22416/1382-4376-2021-31-5-16-24
For citation:
Garbuzenko D.V. Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(5):16-24. (In Russ.) https://doi.org/10.22416/1382-4376-2021-31-5-16-24
Просмотров:
964
Контент доступен под лицензией Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.
Послать статью по эл. почте 
